Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

Abstract

Stephanie M Kaiser, Sruthi Arepalli, Justis P Ehlers Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence: Justis P EhlersCole Eye Institute, Cleveland Clinic, Cleveland, OH, USAEmail [email protected]: Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.Keywords: anti-VEGF, wet age-related macular degeneration, brolucizumab, aflibercept, bevacizumab, ranibizumab, KSI-301

Keywords

• anti-vegf
• wet age-related macular degeneration
• brolucizumab
• aflibercept
• bevacizumab
• ranibizumab
• ksi-301